Rizamig 5mg 1pcs

INDICATIONS AND USAGE
Rizamig® is indicated for the acute treatment of migraine attacks with or without aura in adults.

DOSAGE AND ADMINISTRATION
Single doses of 5 or 10 mg of Rizamig® Tablets is indicated for the acute treatment of migraines in adults. Doses should be separated by at least 2 hours; no more than 30 mg should be taken in any 24-hour period. Dosage adjustment for special case : The choice of dose should therefore be made on an individual basis, weighing the possible benefit of the 10-mg dose with the potential risk for increased adverse events. The safety of treating, on average, more than four headaches in a 30-day period has not been established. Patients receiving propranolol: In patients receiving propranolol, the 5-mg dose of Rizamig® should be used, up to a maximum of 3 doses in any 24-hour period.

CONTRAINDICATIONS
Rizamig® should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal’s variant angina, or other significant underlying cardiovascular disease. As Rizamig® may increase blood pressure, it should not be given to patients with uncontrolled hypertension. Rizamig® is contraindicated in patients who are hypersensitive to rizatriptan or
any of its inactive ingredients.

PRECAUTIONS
Drugs in this class may cause coronary artery vasospasm, patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of CAD or a predisposition to Prinzmetal’s variant angina before receiving additional doses of medication, and should be monitored electrocardiographically. Rizatriptan should be used with caution in patients with moderate hepatic insufficiency. For a given attack, if a patient has no response to the first dose of rizatriptan, the diagnosis of migraine should be reconsidered before
administration of a second dose.

Drug Interactions
Rizatriptan 5 mg should be used in patients taking propranolol. Ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and rizatriptan within 24 hours is contraindicated. Coadministration of rizatriptan and other 5-HT1 agonists within 24 hours of each other is not recommended. Rizatriptan should not be
administered to patients taking MAO-A inhibitors and non-selective MAO inhibitors.

Pregnancy:
There are no adequate and well-controlled studies in pregnant women; therefore, rizatriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.